C
Claudio Viscoli
Researcher at University of Genoa
Publications - 395
Citations - 26532
Claudio Viscoli is an academic researcher from University of Genoa. The author has contributed to research in topics: Aspergillosis & Neutropenia. The author has an hindex of 66, co-authored 394 publications receiving 22550 citations. Previous affiliations of Claudio Viscoli include University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Ben E. De Pauw,Thomas J. Walsh,J. Peter Donnelly,David A. Stevens,John E. Edwards,Thierry Calandra,Peter G. Pappas,Johan Maertens,Olivier Lortholary,Carol A. Kauffman,David W. Denning,Thomas F. Patterson,Georg Maschmeyer,Jacques Bille,William E. Dismukes,Raoul Herbrecht,William W. Hope,Christopher C. Kibbler,Bart Jan Kullberg,Kieren A. Marr,Patricia Muñoz,Frank C. Odds,John R. Perfect,Angela Restrepo,Markus Ruhnke,Brahm H. Segal,Jack D. Sobel,Tania C. Sorrell,Claudio Viscoli,John R. Wingard,Theoklis E. Zaoutis,John E. Bennett +31 more
TL;DR: These revised definitions of invasive fungal disease are intended to advance clinical and epidemiological research and may serve as a useful model for defining other infections in high-risk patients.
Journal ArticleDOI
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
J. Peter Donnelly,Sharon C.-A. Chen,Carol A. Kauffman,William J. Steinbach,John W. Baddley,Paul E. Verweij,Cornelius J. Clancy,John R. Wingard,Shawn R. Lockhart,Andreas H. Groll,Tania C. Sorrell,Matteo Bassetti,Hamdi Akan,Barbara D. Alexander,David R. Andes,Elie Azoulay,Ralf Bialek,Robert W. Bradsher,Stéphane Bretagne,Thierry Calandra,Angela M. Caliendo,Elio Castagnola,Mario Cruciani,Manuel Cuenca-Estrella,Catherine F. Decker,Sujal R. Desai,Brian T. Fisher,Thomas S. Harrison,Claus Peter Heussel,Henrik Jeldtoft Jensen,Christopher C. Kibbler,Dimitrios P. Kontoyiannis,Bart Jan Kullberg,Katrien Lagrou,Frédéric Lamoth,Thomas Lehrnbecher,J. Loeffler,Olivier Lortholary,Johan Maertens,O. Marchetti,Kieren A. Marr,Henry Masur,Jacques F. Meis,C. Orla Morrisey,Marcio Nucci,Luis Ostrosky-Zeichner,Livio Pagano,Thomas F. Patterson,John R. Perfect,Zdenek Racil,Emmanuel Roilides,Marcus Ruhnke,Cornelia Schaefer Prokop,Shmuel Shoham,Monica A. Slavin,David A. Stevens,George Richard Thompson,Jose A. Vazquez,Claudio Viscoli,Thomas J. Walsh,Adilia Warris,L. Joseph Wheat,P. Lewis White,Theoklis E. Zaoutis,Peter G. Pappas +64 more
TL;DR: These updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.
Journal ArticleDOI
ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.
Oliver A. Cornely,Matteo Bassetti,Thierry Calandra,Jorge Garbino,Bart Jan Kullberg,O. Lortholary,O. Lortholary,Wouter Meersseman,Murat Akova,Maiken Cavling Arendrup,S. Arikan-Akdagli,Jacques Bille,Elio Castagnola,Manuel Cuenca-Estrella,J.P. Donnelly,Andreas H. Groll,Raoul Herbrecht,William W. Hope,Henrik Jeldtoft Jensen,Cornelia Lass-Flörl,George Petrikkos,Malcolm Richardson,Emmanuel Roilides,Paul E. Verweij,Claudio Viscoli,Andrew J. Ullmann +25 more
TL;DR: This part of the EFISG guidelines focuses on non-neutropenic adult patients, and liposomal amphotericin B and voriconazole are supported with moderate, and fluconazole with marginal strength for the targeted initial treatment of candidaemia.
Journal ArticleDOI
Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy
Mario Tumbarello,Pierluigi Viale,Claudio Viscoli,Enrico Maria Trecarichi,Fabio Tumietto,Anna Marchese,Teresa Spanu,Simone Ambretti,Francesca Ginocchio,Francesco Cristini,Angela Raffaella Losito,Sara K. Tedeschi,Roberto Cauda,Matteo Bassetti,Matteo Bassetti +14 more
TL;DR: To improve survival, combined treatment with 2 or more drugs with in vitro activity against the isolate, especially those also including a carbapenem, may be more effective than active monotherapy.
Journal ArticleDOI
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
Andrew J. Ullmann,José María Aguado,S. Arikan-Akdagli,David W. Denning,Andreas H. Groll,Katrien Lagrou,Cornelia Lass-Flörl,Russell E. Lewis,Patricia Muñoz,Paul E. Verweij,Adilia Warris,Florence Ader,Florence Ader,Murat Akova,Maiken Cavling Arendrup,Rosemary Ann Barnes,Catherine Beigelman-Aubry,Catherine Beigelman-Aubry,Stijn Blot,Stijn Blot,Stijn Blot,Emilio Bouza,Roger J. M. Brüggemann,Dieter Buchheidt,Jacques Cadranel,Jacques Cadranel,Elio Castagnola,Arunaloke Chakrabarti,Manuel Cuenca-Estrella,George Dimopoulos,George Dimopoulos,Jesús Fortún,Jean-Pierre Gangneux,Jorge Garbino,Werner J. Heinz,Raoul Herbrecht,Claus Peter Heussel,Christopher C. Kibbler,Nikolay Klimko,Bart Jan Kullberg,Christoph Lange,Thomas Lehrnbecher,Jürgen Löffler,Olivier Lortholary,J Maertens,O. Marchetti,Jacques F. Meis,Livio Pagano,Patricia Ribaud,Malcolm Richardson,Emmanuel Roilides,Markus Ruhnke,Maurizio Sanguinetti,Donald C. Sheppard,János Sinkó,Anna Skiada,Maria J G T Vehreschild,Claudio Viscoli,Oliver A. Cornely +58 more
TL;DR: Treatment duration for aspergillosis is strongly recommended based on clinical improvement, degree of immunosuppression and response on imaging, and in refractory disease, where a personalized approach considering reversal of predisposing factors, switching drug class and surgical intervention is also strongly recommended.